Concentrations, Risks, and Uncertainties
|6 Months Ended|
Jun. 30, 2023
|Risks and Uncertainties [Abstract]|
|Concentrations, Risks, and Uncertainties||
17. Concentrations, Risks, and Uncertainties
For the three months ended June 30, 2023 and 2022, revenue from customers representing 10% or more of the consolidated revenue from continuing operations was $14.6 million and $7.1 million, respectively, and $28.2 million and $15.1 million, respectively, for the six months ended June 30, 2023 and 2022. Accounts receivable related to these customers as of June 30, 2023 and December 31, 2022 was $5.8 million and $0, respectively.
Revenue from the U.S. federal government and agencies was $14.0 million and $12.1 million for the three months ended June 30, 2023 and 2022, respectively, and $27.7 million and $23.2 million, respectively, for the six months ended June 30, 2023 and 2022. Accounts receivable related to U.S. federal government and agencies was $1.7 million and $2.5 million as of June 30, 2023 and December 31, 2022, respectively.
The Company generally extends credit on account, without collateral. Outstanding accounts receivable balances are evaluated by management, and accounts are reserved when it is determined collection is not probable. As of June 30, 2023 and 2022, the Company evaluated the realizability of the aged accounts receivable, giving consideration to each customer’s financial history and liquidity position, credit rating and the facts and circumstances of collectability on each outstanding account, and did not have a significant reserve for uncollectible account.
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef